News & Updates
Filter by Specialty:
Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE
The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.
Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE
24 Aug 2022
Infusion-to-injection infliximab switch safe, helps lower risk of IBD relapse for some patients
Switching from intravenous to subcutaneous infliximab appears to be safe and well-accepted, resulting in a reduced risk of relapse in some inflammatory bowel disease (IBD) patients, according to data from the REMSWITCH study.
Infusion-to-injection infliximab switch safe, helps lower risk of IBD relapse for some patients
24 Aug 2022
Probiotics, prebiotics, synbiotics boost metabolism in NAFLD
Patients with nonalcoholic fatty liver disease (NAFLD) who take probiotics, prebiotics, or synbiotics (PPS) may have better energy metabolism, according to a recent study.
